Simplex Papers (533019)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Zero sales and near-zero net loss mean there is no ongoing operational cash burn from the core business.
• Positive ROE of 1.11% suggests the company has some equity base that is not being eroded significantly.
• The micro market cap of ₹5 Cr could attract strategic buyers for a reverse merger or shell acquisition.
• No dividend outgo allows any existing cash to be preserved.

Concerns

• Sales and net profit are zero – no evidence of revenue-generating business.
• ROCE of -34.78% indicates capital employed is being destroyed.
• Piotroski F-Score of 2/9 reflects very poor financial health.
• Book value and promoter holding are N/A, leaving no measure of intrinsic worth or insider confidence.
• P/E of 0.00 and zero dividend yield provide no earnings support.

AI Analysis

When I examine Simplex Papers, I feel like a detective searching for evidence of a business. The financials are almost empty: sales stand at ₹0 Cr, net profit at ₹-0 Cr. A P/E of 0.00 is not a sign of cheapness but a confession that the company produces no earnings. Return on capital employed is -34.78%, meaning the capital tied up in this enterprise is actively losing value. The Piotroski F-Score of 2 out of 9 is a damning report card on financial health. Add a dividend yield of 0% and absolutely no growth in sales or profits, and you have a corporate shell rather than an operating company. If I consider an asset play, I must know the worth of the underlying assets. Here, book value is N/A, and the debt-to-equity is N/A, so I have no balance-sheet anchor. The market price of ₹1,829.95 per share capitalises the company at just ₹5 Cr – a micro-cap that could be a vehicle for a reverse merger or a liquidation. But the 52-week range of ₹1,350.05 to ₹2,094.00 shows price volatility without underlying economic progress. Benjamin Graham taught me to buy with a margin of safety, usually related to net-net working capital. In this case, no such safety can be demonstrated. The positive ROE of 1.11% is trivial and likely the result of interest on cash, not operational strength. There is no moat, no pricing power, no management evidence. I would be speculating, not investing. Simplex Papers fails my first test: it must be a business that can earn a reasonable return on equity over time. This one earns almost nothing. I would keep it on my watchlist only to monitor any corporate actions, audited book value, or capital reorganisation. I want to hear from management why this business exists and what assets it truly holds. Without that, I am buying a mystery. But as an investment today, I can only say: avoid.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer